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Specific elastin degradation 
products are associated with poor 
outcome in the ECLIPSE COPD 
cohort
Sarah Rank Rønnow1,2, Lasse Løcke Langholm1,3, Jannie Marie Bülow Sand1, 
Jeppe Thorlacius-Ussing  1, Diana Julie Leeming1, Tina Manon-Jensen1, Ruth Tal-Singer4, 
Bruce E. Miller4, Morten Asser Karsdal1 & Jørgen Vestbo5
Chronic obstructive pulmonary disease (COPD) is characterized by a slow heterogeneous progression. 
Therefore, improved biomarkers that can accurately identify patients with the highest likelihood 
of progression and therefore the ability to benefit from a given treatment, are needed. Elastin is an 
essential structural protein of the lungs. In this study, we investigated whether elastin degradation 
products generated by the enzymes proteinase 3, cathepsin G, neutrophil elastase, MMP7 or MMP9/12 
were prognostic biomarkers for COPD-related outcomes. The elastin degradome was assessed in a 
subpopulation (n = 1307) of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
End-points (ECLIPSE) cohort with 3 years of clinical follow-up. Elastin degraded by proteinase 3 
could distinguish between COPD participants and non-smoking controls (p = 0.0006). A total of 30 
participants (3%) died over the 3 years of observation. After adjusting for confounders, plasma levels 
of elastin degraded by proteinase 3 and cathepsin G were independently associated with mortality 
outcome with a hazard ratio per 1 SD of 1.49 (95%CI 1.24–1.80, p < 0.0001) and 1.31 (95%CI 1.10–
1.57, p = 0.0029), respectively. Assessing the elastin degradome demonstrated that specific elastin 
degradation fragments have potential utility as biomarkers identifying subtypes of COPD patients at 
risk of poor prognosis and supports further exploration in confirmatory studies.
Disease progression of chronic obstructive pulmonary disease (COPD) is slow and very heterogeneous, this is 
most likely consequent to different phenotypes with different disease trajectories that should be treated individ-
ually1,2. Phase III studies in COPD are long and costly, and consequently, there is a medical need to develop new 
and improved biomarkers that accurately identify COPD patients who progress within a short time period, conse-
quent to a given disease phenotype which may be pharmaceutically attenuated. This is essential for the execution 
of improved phase II clinical studies that will allow confident phase III decision based on actual effects on forced 
expiratory volume in the first second (FEV1)3,4.
Elastin is an essential structural protein of the lungs and is responsible for tissue elasticity5,6. Loss of the elastic-
ity and elastin content during pathological situations is reported in inflammatory diseases including COPD with 
co-existing emphysema7–11. Tropoelastin, the monomeric form of elastin, has a unique structure that is composed 
of highly cross-linked and extremely hydrophobic domains, which renders it resistant to proteolytic degradation 
in healthy conditions12,13. Under pathological conditions such as COPD increased numbers of inflammatory cells 
and fibroblasts leads to an up-regulation of proteases including serine proteinases and matrix metalloproteinases 
(MMPs)14. Both excessive serine proteinase and MMP activity are associated with the destruction of elastin, 
resulting in specific pathological protein fragments and loss of lung elasticity11,15. These proteolytically pro-
cessed fragments also referred to as neoepitopes are released into the circulation and may be assessed as simple 
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non-invasive biomarkers. These neoepitopes represent a unique fingerprint of proteolytic cleavage of the protein 
and may be used to identify whether the tissue is pathologically affected16,17. Neoepitopes have been proven to 
be more accurate predictors of disease than their unmodified intact mature protein18,19, since measurement of 
different fragments from the same protein has yielded different information19–21. For example, such a fragment 
is produced when elastin is degraded by neutrophils elastase which may be assessed as a biomarker (EL-NE) 
associated with chronic inflammation22 and emphysema23. Such a fragment can also be produced by MMP-7 
(ELM7) associated with lung remodeling in IPF10, or by MMP9/12 (ELM12) elevated during acute myocardial 
infarction24. In direct alignment, markers of elastin degraded predominantly by the serine proteinases, proteinase 
3 (ELP-3) and cathepsin G (EL-CG), are also the result of specific elastin degradation providing relations to other 
pathological events in lung diseases25.
We evaluated aspects of degraded elastin by five different proteinases in a subpopulation in the Evaluation of 
COPD Longitudinal to Identify Predictive Surrogate End-points (ECLIPSE) cohort. We hypothesized that dif-
ferent elastin fragments would provide complementary pathophysiological information with the hypothesis that 
MMP, neutrophil elastase, proteinase 3 and cathepsin G activity may play different roles in lung tissue damage in 
COPD. We also tested the hypothesis that these fragments were prognostic of poor clinical outcomes: a decline 
in lung function and mortality.
Results
Elastin fragments have different pathological specificity. The five unique elastin neoepitope bio-
markers investigated in this study were generated from either cleavage of human elastin by proteinase 3 (ELP-3), 
cathepsin G (EL-CG), neutrophil elastase (EL-NE), MMP7 (ELM7) or MMP9/12 (ELM12). ELP-3 correlated 
positively with EL-CG, EL-NE and ELM7 (0.6; 0.36; 0.33), respectively. No significant correlation was observed 
for any of the other neoepitope biomarkers (Fig. 1).
Baseline characteristics of smoking controls, non-smoking controls and a subgroup of age, BMI and 
gender-matched COPD participants are listed in Table 1. As expected, COPD subjects had lower FEV1 and FEV1/
FVC ratio compared to both control groups. Plasma ELP-3 level was significantly up-regulated in COPD when 
compared to levels of non-smoking controls (p = 0.0004), but not when compared to smoking controls (Fig. 2). 
No significant difference was observed for EL-CG, EL-NE, ELM7 and ELM12. Furthermore, no correlation 
Figure 1. Spearman’s coefficient of rank correlations is listed in the table between the elastin biomarkers. The 
darkest color represents the most correlated biomarkers.
Characteristic COPD (n = 100)
Smoker controls 
(n = 99)
non-smoker 
controls (n = 98) P-value
Age (yr) 60 ± 7 60 ± 7 59 ± 7 0.68
Female sex 50 (50) 49 (49) 49 (50) 0.99
Body-mass-index 27 ± 5.7 27 ± 4.3 28 ± 4.5 0.14
Smoking status
   Current smoker 50 (50) 99 (100) 0 (0) 0.002
   Smoking history 
(pack-yr) 40 ± 18 32 ± 17 0 ± 0 <0.0001
Clinical variables
   FEV1 (L) 1.46 ± 0.6 3.08 ± 0.8 3.18 ± 0.8 <0.0001
   FEV1 (% predicted) 48 ± 16 103 ± 15 110 ± 15 <0.0001
   FEV1/FVC 0.47 ± 0.12 0.75 ± 0.06 0.78 ± 0.05 <0.0001
   ELP-3 26.34 ± 15.96 21.39 ± 11.78 18.14 ± 10.30 0.0009
   EL-CG 1.76 ± 1.46 2.25 ± 6.60 1.45 ± 0.71 0.83
   EL-NE 10.31 ± 14.11 10.22 ± 14.72 7.79 ± 5.64 0.36
   ELM7 2.80 ± 1.01 2.65 ± 0.76 2.72 ± 0.67 0.46
   ELM12 4.21 ± 2.83 4.01 ± 3.37 3.70 ± 1.46 0.20
Table 1. Population demographics and characteristics at baseline. Data are shown as mean ± SD, median 
(25th; 75th) or number (%). FEV1, post- bronchodilator forced expiratory volume in 1 second; FVC; forced vital 
capacity. Statistical significance was determined using Kruskal-Wallis test or chi-squared test.
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between the elastin fragments and FEV1 or degree of emphysema defined as more than 10% of lung volume with 
a density of −950 Hounsfield units on inspiratory computed tomography was observed (data not shown).
Elastin degradation by proteinase 3 and cathepsin G is related to mortality. Baseline character-
istics for survivors and non-survivors are listed in Table 2. Non-survivors were significantly older, had increased 
mMRC dyspnea score, a higher number of previous exacerbations, a lower use of inhaled corticosteroids, and 
fewer subjects were current smokers (Table 2). A total of 30 (3%) out of the 1000 COPD participants assessed died 
over the three years of observation. ELP-3 was significantly increased in non-survivors compared to survivors 
(p = 0.0202). No significant increase in EL-CG, EL-NE, ELM7 and ELM12 was observed (Fig. 3). After adjusting 
for relevant covariates, plasma levels of ELP-3 and EL-CG were independently associated with mortality with a 
hazard ratio per 1 SD increase in biomarker level of 1.49 [95%CI 1.24–1.80, p < 0.0001] and 1.31 [95%CI 1.10–
1.57, p = 0.0029], respectively. Moreover, in adjusted analysis, the odds ratio for belonging to the highest quartile 
as compared to the lowest quartile was significantly associated with all-cause mortality for ELP-3 and EL-CG 
(2.52 [95%CI 1.62–3.79, p < 0.0001] and 1.74 [95%CI 1.22–2.46, p = 0.0019], respectively) (Fig. 4).
Discussion
There is a medical need for developing new and improved biomarkers to identify COPD subjects with a rapid 
disease progression, who potentially have a higher chance of benefitting from a symptom modifying COPD treat-
ment. Here we investigated elastin degradation fragments, so-called neoepitopes, as blood-based biomarkers 
of disease progression for COPD in a non-invasive manner. We found that elastin degraded by protease 3 and 
cathepsin G, was associated with a higher risk of mortality in subjects with COPD.
Elastin is a unique signature protein of the lungs. Consequently, biomarkers generated from elastin could 
be associated with higher tissue accuracy and pathophysiological relevance; although these neoepitopes could 
potentially arrive from other organs than the lung. The importance of proteolytic elastin degradation in COPD 
is highlighted by the observation that exacerbations in COPD are associated with accelerated elastin turnover4,10. 
Desmosine and isodesmosine have long been proposed as biomarkers of lung tissue destruction as they are the 
crosslinking elements of elastin, released during lung tissue destruction26. It has been demonstrated that subjects 
with COPD have higher levels of plasma desmosine and that levels are able to predict mortality27 which is in 
concordance with our findings. Moreover, a study with 349 subjects with one-third suffering from COPD showed 
that urinary desmosine was significantly correlated with all lung function measures28. This underlines the impor-
tance of elastin degradation as a potential biomarker in COPD, however, the desmosine technology identifies 
non-specific elastin fragments that are being generated through many different processes, both physiological and 
pathophysiological. The technique and biomarkers used in the present study allowed for investigation of elastin 
degradation predominantly produced by specific proteinases, known to be up-regulated in respiratory diseases 
and therefore more carefully quantify the aspects of the elastin degradome10,22–24.
Plasma levels of ELP-3 and EL-CG were associated with all-cause mortality in COPD implying that proteinase 
3 and cathepsin G play a significant role in COPD. During the progression of COPD, inflammatory cells infiltrate 
the lungs, which has been shown to release proteinase 3, cathepsin G and neutrophil elastase into the lungs29. 
These proteinases are known to efficiently degrade elastin30, which is in concordance with the results from this 
study where a higher degree of ELP-3 or EL-CG was significantly associated with a poor outcome. Moreover, pro-
teinase 3 activity was present in the sputum of COPD subjects in a higher amount than the activity of neutrophil 
elastase implicating a bigger role for proteinase 3 in COPD than previously thought31. This may in part explain 
why ELP-3 demonstrated a better association with outcomes relative to EL-NE. Since plasma levels of ELP-3 and 
EL-CG were associated with all-cause mortality, a correlation with FEV1 might have been expected, as this was 
previously observed for desmosine28. In general, the FEV1 decline for the subpopulation of ECLIPSE studied here 
were associated with a considerable intra and inter-person variability which makes an evaluation of predictive 
Figure 2. Serological elastin neo-epitope biomarker levels in age, gender and BMI matched COPD (n = 100), 
smoker controls (n = 99) and non-smoker controls (n = 98). ELP-3 was significantly up-regulated in COPD 
patient compared to non-smoker controls. Data were analyzed using Kruskal-Wallis test and presented as a 
Tukey box plot. Asterisks indicate statistical significance *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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biomarkers for lung function decline challenging, 31% improved or slightly decreased in FEV1 while only 38% 
participants in the entire cohort demonstrated significant FEV1 decline32.
The importance of unique elastin fragments has been emphasized by the fact that they can act as chemotac-
tic peptide for different cell types, showing their ability to function as matrikines33. The hexapeptide VGVAPG 
within tropoelastin is well known for its chemotactic activity attracting monocytes and fibroblasts and its ability 
to regulate MMP expression and activity34,35. Likewise, other fragments of elastin corresponding to XGXXPG, 
where X is a generic hydrophobic residue, has also been shown to be active peptides35–37. In fact, the ELM12 frag-
ment holds the sequence VGVAPG in its peptide, which indicates that it might be a matrikine, however, in the 
current study, no pathological relevance of this biomarker was observed.
The emphysema phenotype, such as the multi-organ loss of tissue (MOLT), is currently receiving increased 
attention, and high elastin turnover could be associated with it, which has been shown by others23,38,39. In accord-
ance with our findings, another study measuring plasma desmosine in the ECLIPSE cohort was not able to show 
a relationship between emphysema and elastin degradation27. The lack of association could be explained by the 
fact that COPD participants from the ECLIPSE cohort had an established disease (GOLD II-IV) with a stable 
state during sampling. This could result in less elastin present in their lungs or a lower disease activity than dur-
ing an exacerbation, which could explain why elastin degradation is not associated or increased in subjects with 
emphysema in this cohort.
The limitations of this study include the low number of deceased subjects, even though we were able to detect 
a significant association with all-cause mortality for the two biomarkers ELP-3 and EL-CG. To generalize these 
finding to a more general COPD population they have to be confirmed in secondary cohorts. Furthermore, 
using the subpopulation of the full ECLIPSE study comprising the study participant that progress the least and 
most in terms of FEV1 decline during the study period might explain the low number and make a less optimal 
Characteristic
Survivors 
(n = 970)
Non-survivors 
(n = 30) P-value
Age (yr) 63 ± 7 68 ± 6 P < 0.0001
Female sex 351 (36) 11 (37) P = 0.14
Body-mass-index 27 ± 5.8 28 ± 7.4 P = 0.80
Smoking status
   Current smoker 364 (38) 3 (10) P = 0.002
   Smoking history (pack-yr) 47 ± 25 56 ± 42 P = 0.92
Clinical variables
   FEV1 (L) 1.42 ± 0.5 1.35 ± 0.5 P = 0.41
   FEV1 (% predicted) 46 ± 15 46 ± 13 P = 0.99
   GOLD stage P = 0.708
   II 480 (50) 14 (47)
   III 390 (40) 14 (47)
   IV 98 (10) 2 (6.7)
   Number of previous exacerbations P = 0.0170
   0 432 (45) 10 (33)
   1 244 (25) 12 (40)
   2 144 (15) 0 (0)
   >2 148 (15) 8 (27)
   mMRC dyspnea score 1 (1;2) 2 (1;3) P = 0.023
   %LLA 16 ± 11 17 ± 11 P = 0.45
   BODE index 3 (1;4) 3.5 (2;5) P = 0.063
Treatments
Inhaled corticosteroids 139 (14) 3 (10) P = 0.048
   Systemic corticosteroids 8 (0.8) 0 P = 0.77
   Statins 237 (24) 6 (20) P = 0.37
Biomarkers
   ELP-3 26.8 ± 15.7 41.7 ± 32.7 P = 0.020
   EL-CG 1.7 ± 1.3 2.6 ± 2.6 P = 0.066
   EL-NE 10.1 ± 9.7 11.8 ± 8.8 P = 0.16
   ELM7 2.8 ± 0.9 3.0 ± 1.0 P = 0.16
   ELM12 4.5 ± 5.5 5.1 ± 5.4 P = 0.22
Table 2. Population demographics and characteristics at baseline. Data are shown as mean ± SD, median (25th; 
75th) or number (%). FEV1, post-bronchodilator forced expiratory volume in 1 second; GOLD, global initiative 
for chronic obstructive lung disease; mMRC, modified Medical Research Council dyspnea scale; %LLA, percent 
low areas of attenuation below 950 Hounsfield unit; BODE, BMI, airflow obstruction, dyspnea and exercise 
capacity index. Statistical significance was determined using Mann-Whitney U test or chi-squared test.
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subpopulation to study mortality. In addition, the ELP-3, EL-CG, ELM7 and ELM12 was measured in heparin 
plasma at year 1, whereas EL-NE was measured in 6-month serum. This could create some difficulties in directly 
comparing the results.
Conclusion
In conclusion, we have demonstrated that five cleavage-specific fragments of elastin generated by five differ-
ent proteinases reflect different pathological processes in COPD. ELP-3 and EL-CG demonstrated promise as 
prognostic biomarkers for all-cause mortality reflecting an increase of elastin remodeling by proteinase 3 and 
cathepsin G. This study demonstrated the importance of evaluating elastin turnover in the pathology and natural 
history of COPD.
Figure 3. Serological elastin neo-epitope biomarker levels in survivors (n = 970) and non-survivors (n = 30). 
ELP-3 was significantly elevated in non-survivors compared to survivors. Data were analyzed using Mann-
Whitney test and presented as a Tukey box plot. Asterisks indicate statistical significance *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001.
Figure 4. Cox proportional hazard ratio on the left figure and odds ratio for patients belonging to biomarker 
quartile 4 vs 1 on the right figure. Data are shown as mean (95% CI) hazard ratio for 1 log SD increase in 
biomarker for all-cause mortality and adjusted for age, smoking status, BODE index, mMRC dyspnea score, 
inhaled corticosteroids and number of exacerbations the previous year of study start. Asterisks indicate 
statistical significance *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Biomarker Specification Sequence Location Reference
ELP-3 Elastin degraded by proteinase 3 LPGGYGLPYT 213–222 25
EL-CG Elastin degraded by cathepsin G LGGVAARPGF 756–765 25
EL-NE Elastin degraded by neutrophil elastase GGPGFGPGVV 325–334 22
ELM7 Elastin degraded by MMP7 IKAPKLPGGY 208–217 15
ELM12 Elastin degraded by MMP12 or MMP9 GVAPGIGPGG 543–552 42
Table 3. Biomarker specifications.
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Methods
Study design and participants. The analysis was based on the three-year observational longitudinal study 
ECLIPSE (ClinicalTrials.gov. number, NCT00292552), described previously32,40. The full ECLIPSE study included 
2163 participants with COPD. The enrollment criteria included an FEV1 of less than 80% of the predicted value 
and a FEV1/forced vital capacity (FVC) ratio of 0.7 or less assessed after the use of bronchodilators. COPD partici-
pants had a smoking history of 10 or more pack-years. 343 smoking controls with a smoking history of 10 or more 
pack-years and 223 nonsmoking controls were also included in the study. The controls had an FEV1 of more than 
85% of the predicted value and an FEV1/FVC ratio of 0.7 or more after the use of bronchodilators. Control partic-
ipants had to be free of significant comorbidities, determined from screening investigation, physical examination 
and medical history. Eight study visits were conducted at baseline, month three, six and subsequently every six 
months over three years. The current analysis was performed on 1307 participants consisting of 1000 COPD, 207 
smoking controls and 100 non-smoking controls. All-cause mortality was recorded until year 3. The study was 
conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by 
relevant ethics and review boards (Supplementary Table 1). Participants provided informed consent.
Quantification of serological biochemical biomarkers. Whole blood was collected from fasting par-
ticipants and transferred to vacutainers containing sodium heparin. Plasma was obtained by centrifugation of 
vacutainer tubes at 2,000 g for 10–15 minutes and stored at −80 °C until analysis. Elastin degradation by protein-
ase 3 (ELP-3), cathepsin G (EL-CG) and MMP9/12 (ELM12) was measured in heparin plasma obtained from 
1307 study participants at the year 1 visit using well-validated ELISAs each utilizing monoclonal antibodies tar-
geting a specific neoepitope (Nordic Bioscience, Herlev, Denmark), see specifications in Table 3. Measurements 
were performed in a blinded manner according to the instruction of the manufactures. Previously, elastin deg-
radation by neutrophil elastase (EL-NE) was measured in month six serum samples whereas elastin degraded by 
MMP7 (ELM7) was measured in year 1 heparin plasma41. The five unique elastin neoepitope biomarkers inves-
tigated in this study ELP-3, EL-CG, EL-NE, ELM7 and ELM12 originates from locations throughout the tropoe-
lastin (Fig. 5) and are very different in terms of activation, inhibition, substrate specificity and source (Table 4).
Statistical analysis. Population demographics were compared using Kruskal-Wallis test, Mann-Whitney 
U test and chi-squared test as appropriate. Kruskal-Wallis test and Mann-Whitney test were used to compare 
biomarker levels between COPD subjects, controls, survivors and non-survivors. Cox proportional hazard 
regression was used to assess the prognostic value of each biomarker for all-cause mortality for one standard 
Proteinase
Substrate 
specificity
Optimal 
pH for 
activity Source Activation Activation enzyme Inhibitors
Proteinase 3
Small hydrophobic 
residues at P1: 
Val, Cys, Ala, Met, 
Leu, Ser
~8.0
Neutrophils
Monocytes
Basophils
Cleavage of N-terminal signal peptide 
and then cleavage of N-terminal 
prodipeptide =  > enzymatic activity 
and the C-terminal
Dipeptidyl 
peptidase I
α2-macroglobulins, α1-PI, 
SerpinB1, α1-ACT, Elafin, 
Eglin c
Cathepsin G
Aromatic or 
positively charged 
residue at P1: Phe, 
Tyr, Lys, Arg
~7.5
Neutrophils
Monocytes
Mastocytes
Cleavage of N-terminal signal peptide 
and then cleavage of N-terminal 
prodipeptide = > enzymatic activity 
and the C-terminal
Dipeptidyl 
peptidase I
β-ketophosphonic acids, 
aminoalkylphosphonic 
esters and boswellic acids
Neutrophil elastase
Small hydrophobic 
residues at P1: Val, 
Cys, Ala, Met, Ile, 
Leu, Ser
8.0–8.5 NeutrophilsMonocytes
Cleavage of N-terminal signal peptide 
and then cleavage of N-terminal 
prodipeptide = > enzymatic activity 
and the C-terminal
Dipeptidyl 
peptidase I
α2-macroglobulins, α1-PI, 
SerpinB1, α1-ACT, Elafin, 
Eglin c
MMP7 Acidic residues P1: Leu, Ile, Val, Met 7.0 Macrophages lymphocytes
Proteolytic cleavage resulting in 
removal of the prodomain, final step 
is autolytic cleavage at Glu77↓Tyr78
Trypsin, plasmin, 
MMp-3, MMP10 
and others
TIMPs, 
1,10-phenanthroline, DTT
MMP9 Small residues P1: Gly, Ala, Ser 7.5 Macrophages lymphocytes
Proteolytic removal of the N-terminal 
propeptide involving a cysteine 
switch mechanism
Matrilysin, 
interstitial 
collagenase, tissue 
kallikrein, plasmin, 
macrophage elastase
TIMPs
MMP12 P1: Leu, 8.0 Macrophages Protelytic removal of the prodomain and the C-terminal
Trypsin, plasmin, 
neutrophil elastase, 
stromelysin-1
TIMP-1, α2-macroglobulin, 
1,10-phenanthroline
Table 4. Proteinase characteristics.
Figure 5. Schematic figure of tropoelastin and the location of the five unique elastin neoepitope biomarkers 
generated from either cleavage of human elastin by proteinase 3 (ELP-3), cathepsin G (EL-CG), neutrophil 
elastase (EL-NE), MMP7 (ELM7) or MMP9/12 (ELM12).
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deviation (SD) increase in biomarker level. Logistic regression was used to find the odds ratio for all-cause mor-
tality belonging to the upper quartile versus the lower quartile. The risk of death was assessed adjusted for con-
founders that were significantly different between survivors and non-survivors. The covariates adjusted for were 
age, smoking status, mMRC dyspnea score, use of inhaled corticosteroids and number of exacerbations in the 
year prior to blood sampling.
The software MedCalc (MedCalc version 14.8.1, MedCalc software bvba, Ostend, Belgium) was used to per-
form all statistical analysis.
Data Availability
The dataset generated during and analyzed during the current study are available from the corresponding author 
on reasonable request.
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